

DAFTAR PUSTAKA

- American Thoracic Society, 2007. *An Official ATS / IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases*.
- Brooks, G.F., Carroll, K.C., Butel, J.S., Morse, S.A., Mietzner, T.A., 2010. *Jawetz, Melnick & Adelberg's Medical Microbiology 25th edition*. Lange, US
- Brown-elliott, B.A., Nash, K.A., Wallace, R.J., 2012. *Antimicrobial Susceptibility Testing , Drug Resistance Mechanisms , and Therapy of Infections with Nontuberculous Mycobacteria* 25, 545-582.
- Casal, M.J., Rodriguez, F.C., Benavente, M.C., 1985. *In Vitro Susceptibility of Mycobacterium fortuitum and Mycobacterium chelonae to Cefmetazole* 27, 282-283.
- Cavusoglu, C., Gurpinar, T., Ecemis, T., 2012. *Evaluation of antimicrobial susceptibilities of rapidly growing mycobacteria by Sensititre RAPMYCO panel* 73-76.
- Chien, J., Lai, C., Sheng, W., Yu, C., Hsueh, P., Study, T., 2014. *Pulmonary Infection and Colonization with Nontuberculous Mycobacteria, Taiwan, 2000-2012* 20, 0-3.
- CLSI, 2010a. *Susceptibility Testing of Mycobacteria , Nocardiae , and Other Aerobic Actinomycetes; Approved Standard*. Clinical and Laboratory Standards Institute, Wayne, PA.
- CLSI, 2010b. *Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement*. Clinical and Laboratory Standards Institute, Wayne, PA.
- Ho, Y.I.I., Chan, C.Y., Cheng, A.F.B., 1997. *In-vitro activities of aminoglycoside-aminocyclitols against mycobacteria* 27-32.

- Hong-xiu, W., 2010. *Nontuberculous mycobacteria: susceptibility pattern and prevalence rate in Shanghai from 2005 to 2008* 123, 184-187.
- Huang, C.-W., Chen, J.-H., Hu, S.-T., Huang, W.-C., Lee, Y.-C., Huang, C.-C., Shen, G.-H., 2013. *Synergistic activities of tigecycline with clarithromycin or amikacin against rapidly growing mycobacteria in Taiwan*. *Int. J. Antimicrob. Agents* 41, 218-23.
- Jorgensen, J.H., Ferraro, M.J., 2009. *Antimicrobial Susceptibility Testing: A Review of General Principles and Contemporary Practices AND THE RATIONALE FOR PERFORMING* 7750, 1749-1755.
- Katzung, B. G. 2012. *Basic & Clinical Pharmacology*. Singapore: McGraw-Hill
- Lee, M.Y., Lee, T., Kim, M.H., Byun, S.S., Ko, M.K., Hong, J.M., Kim, K.H., Ra, S.W., Seo, K.W., Jegal, Y., Jeong, J., Ahn, J.J., 2014. *Regional differences of nontuberculous mycobacteria species in Ulsan, Korea*. *J. Thorac. Dis.* 6, 965-70.
- Li, G., Lian, L., Wan, L., Zhang, J., Zhao, X., Jiang, Y., Zhao, L., Liu, H., Wan, K., 2013. *Antimicrobial Susceptibility of Standard Strains of Nontuberculous Mycobacteria by Microplate Alamar Blue Assay* 8, 4-9.
- Nash, K. a, Brown-Elliott, B. a, Wallace, R.J., 2009. *A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae*. *Antimicrob. Agents Chemother.* 53, 1367-76.
- Nessar, R., Cambau, E., Reytrat, J.M., Murray, A., Gicquel, B., 2012. *Mycobacterium abscessus: a new antibiotic nightmare*. *J. Antimicrob. Chemother.* 67, 810-8.
- Rastogi, N., Legrand, E., Sola, C., 2001. *The mycobacteria: an introduction to nomenclature and pathogenesis* 20, 21-54.

Sabry, N., 2011. *Mycobacterium tuberculosis*.

Shen, G., Wu, B., Wu, K., Chen, J., 2007. *In Vitro Activities of Isepamicin , Other Aminoglycosides , and Capreomycin against Clinical Isolates of Rapidly Growing Mycobacteria in Taiwan* 51, 1849-1851.

Simons, S., 2011. *Nontuberculous Mycobacteria in Respiratory Tract Infections, Eastern Asia*. Emerg. Infect. Dis. 17.

Swenson, J.M., Wallace, R.J., Silcox, V.A., Thornsberry, C., 1985. *Antimicrobial Susceptibility of Five Subgroups of Mycobacterium fortuitum and Mycobacterium chelonae* 28, 807-811.

Tomford, J.W., 2014. *Nontuberculous Mycobacterial Disorders* 1-20.

Wallace, R.J., Dalovisio, J.R., Pankey, G.A., 1979. *Disk Diffusion Testing of Susceptibility of Mycobacterium fortuitum and Mycobacterium chelonae to Antibacterial Agents* 16, 611-614.

Wallace, R. J., Jr., J. M. Swenson, V. A. Silcox, and M. G. Bullen. 1985. *Treatment of nonpulmonary infection due to Mycobacterium fortuitum and Mycobacterium chelonae on the basis of in vitro susceptibility*. Journal of Infectious Diseases. 152:500-514

WHO. 2008. *Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs*. 1-20. Geneva.

Woods GL. 2011. *Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes; approved standard*. CLSI document M24-A2. Clinical and Laboratory Standards Institute, Wayne, PA.